Showing results (841-850 of 1,033) with videos related to

Sort By:
Pageof 104
The Lancet. Respiratory Medicine|September 1, 2022
Pulse oximetry for the diagnosis and management of acute respiratory distress syndromeKatherine D Wick, Michael A Matthay, Lorraine B Ware
The Lancet. Respiratory Medicine|January 20, 2022
The global prevalence and ethnic heterogeneity of primary ciliary dyskinesia gene variants: a genetic database analysisWilliam B Hannah, Bryce A Seifert, Rebecca Truty, et al.
The Lancet. Respiratory Medicine|January 11, 2022
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trialEvelijn S Lourijsen, Sietze Reitsma, Marleen Vleming, et al.
The Lancet. Respiratory Medicine|January 16, 2022
Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a national incident cohort studyTing Shi, Jiafeng Pan, Eleftheria Vasileiou, et al.
The Lancet. Respiratory Medicine|January 25, 2021
Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trialBarry Dixon, Roger J Smith, Duncan J Campbell, et al.
The Lancet. Respiratory Medicine|December 13, 2016
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trialGanesh Raghu, Kevin K Brown, Harold R Collard, et al.
The Lancet. Respiratory Medicine|March 28, 2017
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosisKeertan Dheda, Tawanda Gumbo, Gary Maartens, et al.
The Lancet. Respiratory Medicine|February 13, 2017
Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studiesMaryam Darvishian, Edwin R van den Heuvel, Ange Bissielo, et al.
The Lancet. Respiratory Medicine|April 12, 2017
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialGeoffrey L Chupp, Eric S Bradford, Frank C Albers, et al.
The Lancet. Respiratory Medicine|December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trialBenjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
Pageof 104